Chimin Health Management Hits Day Low at CNY 10.03 Amid Price Pressure

Chimin Health Management Co., Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock dropping by 6.01% as of October 13, 2025. The stock reached an intraday low of CNY 10.03, reflecting ongoing challenges within the company. Over the past week, Chimin Health has seen a 9.31% decrease, and its performance over the last month has been even more pronounced, with a decline of 19.25%. Despite a notable 60.25% increase over the past year, the company has faced difficulties, including a negative trend in net sales, which have contracted at an annual rate of 1.80%. Additionally, the operating profit has shown a concerning decline of 232.73% over the last five years. Chimin Health's financial metrics reveal a debt-to-equity ratio of 0.24, indicating a relatively low level of debt. However, the company has reported negative results for the last two consecutive quarters, with a pre-tax profit of CNY -42.78 million, down 69.12%. As the stock continues to navigate these challenges, its performance remains closely monitored within the market.